OV secures new Drug Response Predictor for potential new drug candidate

Hoersholm, Denmark; July 5th, 2016 – Oncology Venture Sweden AB (OV:ST) announces the acquisition of a new DRP from Medical Prognosis Institute for a selected, undisclosed anti-cancer drug candidate. By this OV and MPI enhances their collaboration to improve the lives of cancer patients by developing new Personalized Medicine treatment options.

Oncology Venture is finding anti cancer drugs that have achieved encouraging levels of complete and partial responses but not with a high enough response rate to secure approval. The drugs will, if they continue to fulfill OV’s requirements and are successfully inlicensed, be developed with MPI’s DRP™ to enrich the patient population and increase the response rate.

"It is encouraging that MPI can develop strong Drug Response Predictors for Oncology Ventures anti cancer drug development program. The aim is to inlicense and develop 5 anti-cancer drugs whereof 2 are expected to be approved - giving cancer patients a new Personalized Treatment option". Our belief is that the DRP™ platform will provide the right assistance to reach the clinical success levels required for authority approval.”, says Adjunct Professor Peter Buhl Jensen, M.D., PhD and CEO of Oncology Venture.

About the Drug Response Predictor DRP™ Screening Tool

Oncology Venture uses Medical Prognosis’ DRP™ Screening Tool to select patients who by the gene signature of their cancer have a high likelihood to respond to a certain drug. The goal is to develop the drug for the right patients, and by screening patients before treatment the response rate can be significantly increased.

The DRP™ method builds on the comparison of sensitive vs. resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. The microRNA based DRP™ is used on certain products where the DRP™ based on messenger RNA is more broadly useful and more validated.

For further information, please contact

Ulla Hald Buhl, COO and
Chief IR & Communications
Mobile: +45 2170 1049
   or    Peter Buhl Jensen, CEO
Mobile: +45 21 60 89 22
E-mail: pbj@oncologyventure.com

About Oncology Venture Sweden AB

Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction – DRP™ – in order to significantly increase the probability of success in clinical trials. DRP™ has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that betters the odds compared to traditional pharmaceutical development. Instead of treating all patients suffering from a particular type of cancer, patients are first screened, and only those most likely to respond to the treatment will be treated. With a more defined patient group, risks and costs are reduced, and the process of drug development becomes more efficient.

Our current product portfolio: LiPlaCis, an intelligent liposomal formulation of cisplatin for Breast Cancer, Irofulven, developed from a fungus, for Prostate Cancer, and APO010, an immuno-oncology product for Multiple Myeloma.


Documents & Links